Feature Channels:

Immunology

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Colon Cancer, GI cancer, Oncology, Microbiome, Rectal Cancer, Colorectal Cancer

The New Face of Colon Cancer

091fl_hr_javaputsranch-2.jpg

Of the 1,000 GI cancer patients seen at his clinic last year, nearly half were under age 50, says John L. Marshall, MD, director of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center and chief of hematology and oncology at MedStar Georgetown University Hospital. Many are in their 20s and 30s; one was just 17.

Medicine

Channels:

New Prostate Cancer Guidelines, Vocal Chord Cancer, Aggressive Ovarian Cancer, and More in the Cancer News Source

Click here to go directly to the Cancer News Source

Medicine

Channels:

Mount Sinai Health System, Lung Cancer, Immunotherapy, PD-1, PD-1 blockade, PD-L1 checkpoint inhibitors, Thoracic Surgery

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 4-May-2017 12:00 PM EDT

Medicine

Channels:

Sarcoma, Cancer, Immunotherapy, checkpoint inhibitors, immune activation

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 2-May-2017 11:00 AM EDT

Medicine

Channels:

ESGC, glottic cancer, HFX, hypofractionated radiotherapy, Journal Of The National Cancer Institute, Yale Cancer Center

Yale Researchers Identify Optimal Therapy for Patients with Early-Stage Glottic Cancer (Vocal Chord Cancer)

ESGCOSfigure_2.jpg

Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC), a cancer of the vocal chords, however, the optimal radiation treatment schedule remains unknown, until now.

Medicine

Channels:

Immunotherapy, Maraba, non-small cell lung cancer

Hamilton Patient First to Receive Experimental Immunotherapy Combination for Cancer in Clinical Trial

Experts at Hamilton Health Sciences (HHS) and McMaster University, in partnership with The Ottawa Hospital, have begun a clinical trial to determine if the unique experimental immunotherapy combination may be able to treat non-small cell lung cancer. The experimental therapy combines two different viruses with an approved drug to stimulate the immune system to recognize and attack cancer cells.

Medicine

Channels:

Glaucoma in Developing Countries, Reversing Retinitis Pigmentosa, Eye Expressions, and More in the Vision News Source

The latest research and feature news on vision in the Vision News Source

Medicine

Channels:

Cancer, Ovarian Cancer, Biomarker, Cancer Research, NY-ESO-1, Immunotherapy, Targeted Therapy, Tumor Antigens

Roswell Park-Led Team Identifies Tumor Marker for Aggressive Ovarian Cancer

KunleOdunsiwithGYNPatient2013-08-283.jpg

Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published online ahead of print in the journal Gynecologic Oncology.

Medicine

Channels:

Cancer, Research, Immunotherapy, CAR T cells, Cellular Therapy, Biotechnology, Biomedical, Solid Tumors, Biopolymer

Implanted Scaffold with T Cells Rapidly Shrinks Tumors

3.jpg

A biopolymer structure enriched with nutrients shows how immunotherapy could be adapted for solid tumors, according to study in The Journal of Clinical Investigation.

Medicine

Science

Channels:

Preeclampsia, Immune

Altered Immune Cells May Both Contribute to Preeclampsia and Offer New Hope for Treatment

In a new study presented today at the APS annual meeting at Experimental Biology 2017, researchers have found that the immune system’s natural killer (NK) cells activate and change in response to placental ischemia. Disrupting these altered cells seems to blunt some of the dangerous complications of the condition, including high blood pressure (hypertension) and inflammation in the mother and growth restriction in the fetus.







Chat now!